{
    "clinical_study": {
        "@rank": "99281", 
        "arm_group": {
            "arm_group_label": "olanzapine", 
            "description": "15-25mg/day for 24 weeks"
        }, 
        "brief_summary": {
            "textblock": "Almost all of antipsychotics can induce metabolic syndrome,Genetic factors play a key role\n      in the development of metabolic syndrome,TCF7L2 and SLC30A8 are strongestly correlated with\n      metabolic syndrome.Moreover,Antipsychotics have an effect on the expression of TCF7L2 and\n      SLC30A8 genes.It indicates the variations of TCF7L2 and SLC30A8 play an important part in\n      the development of antipsychotics-induced metabolic syndrome."
        }, 
        "brief_title": "The Mechanism of TCF7L2 and SLC30A8 on Antipsychotic-induced Metabolic Syndrome", 
        "completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Schizophrenia", 
            "Metabolic Syndrome"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Schizophrenia", 
                "Metabolic Syndrome X"
            ]
        }, 
        "detailed_description": {
            "textblock": "-  In this study, we will determine the effect of olanzapine on the expression of TCF7L2\n           and SLC30A8.\n\n        -  The relationship of the polymorphism of TCF7L2 and SLC30A8 with antipsychotic-induced\n           metabolic syndrome in schizophrenia patients."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Clinical diagnosis of first episode schizophrenia\n\n          -  Must be able to swallow tablets\n\n          -  Take only one antipsychotics\n\n        Exclusion Criteria:\n\n          -  liver or renal  or cardiovascular diseases\n\n          -  pregnant or lactating women\n\n          -  drug and alcohol dependence"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "All participants met the Diagnostic and Statistical Manual of Mental Disorder-Fourth\n        Edition (DSM-IV) criteria for first episode schizophrenia.All of the patients and their\n        familier are know of the study and sign the informed consent."
            }
        }, 
        "enrollment": {
            "#text": "212", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 20, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02093858", 
            "org_study_id": "RRW"
        }, 
        "intervention_browse": {
            "mesh_term": "Antipsychotic Agents"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Metabolic Syndrome", 
        "lastchanged_date": "March 20, 2014", 
        "location": {
            "contact": {
                "email": "wurenrong2013@163.com.cn", 
                "last_name": "Renrong Wu, PhD", 
                "phone": "86-15874179855"
            }, 
            "facility": {
                "address": {
                    "city": "Changsha", 
                    "country": "China", 
                    "state": "Hunan", 
                    "zip": "410011"
                }, 
                "name": "Mental Health Institute"
            }, 
            "investigator": {
                "last_name": "Renrong Wu, Doctor", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_groups": "1", 
        "official_title": "The Mechanism of TCF7L2 and SLC30A8 on Antipsychotic-induced Metabolic Syndrome", 
        "other_outcome": {
            "measure": "Change of serum insulin", 
            "safety_issue": "No", 
            "time_frame": "24 weeks"
        }, 
        "overall_contact": {
            "email": "wurenrong2013@163.com", 
            "last_name": "RenRong Wu, PhD", 
            "phone": "0731-85554052"
        }, 
        "overall_official": {
            "affiliation": "Central South University", 
            "last_name": "Wu R Rong, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change in weight and blood glucose", 
            "safety_issue": "Yes", 
            "time_frame": "24 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02093858"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Central South University", 
            "investigator_full_name": "Renrong Wu", 
            "investigator_title": "PhD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Change of the blood pressure and blood lipid", 
            "safety_issue": "Yes", 
            "time_frame": "24 weeks"
        }, 
        "source": "Central South University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Central South University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "March 2014"
    }
}